CY1124894T1 - Θεραπευτικη αντιμετωπιση χολοστατικου κνησμου με σελαδελπαρη - Google Patents

Θεραπευτικη αντιμετωπιση χολοστατικου κνησμου με σελαδελπαρη

Info

Publication number
CY1124894T1
CY1124894T1 CY20221100017T CY221100017T CY1124894T1 CY 1124894 T1 CY1124894 T1 CY 1124894T1 CY 20221100017 T CY20221100017 T CY 20221100017T CY 221100017 T CY221100017 T CY 221100017T CY 1124894 T1 CY1124894 T1 CY 1124894T1
Authority
CY
Cyprus
Prior art keywords
seladelpar
cholestatic
itching
therapeutic treatment
treatment
Prior art date
Application number
CY20221100017T
Other languages
Greek (el)
English (en)
Inventor
Pol Boudes
Charles A. Mcwherter
Alexandra S. STEINBERG
Original Assignee
Cymabay Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics, Inc. filed Critical Cymabay Therapeutics, Inc.
Publication of CY1124894T1 publication Critical patent/CY1124894T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Ladders (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CY20221100017T 2017-09-26 2022-01-07 Θεραπευτικη αντιμετωπιση χολοστατικου κνησμου με σελαδελπαρη CY1124894T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762563395P 2017-09-26 2017-09-26
PCT/US2018/052490 WO2019067373A1 (en) 2017-09-26 2018-09-24 TREATMENT OF CHOLESTATIC PRURIT

Publications (1)

Publication Number Publication Date
CY1124894T1 true CY1124894T1 (el) 2023-01-05

Family

ID=64564950

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100017T CY1124894T1 (el) 2017-09-26 2022-01-07 Θεραπευτικη αντιμετωπιση χολοστατικου κνησμου με σελαδελπαρη

Country Status (26)

Country Link
US (2) US20190105291A1 (https=)
EP (3) EP3973959B8 (https=)
JP (1) JP7023371B2 (https=)
KR (1) KR102376794B1 (https=)
CN (1) CN111132675B (https=)
AU (2) AU2018342323B2 (https=)
BR (1) BR112020005074A2 (https=)
CA (1) CA3076614C (https=)
CY (1) CY1124894T1 (https=)
DK (1) DK3973959T3 (https=)
ES (2) ES3012120T3 (https=)
FI (1) FI3973959T3 (https=)
HR (2) HRP20212010T1 (https=)
HU (2) HUE057377T2 (https=)
IL (2) IL273569B (https=)
LT (2) LT3687523T (https=)
MX (1) MX392537B (https=)
PL (2) PL3973959T3 (https=)
PT (2) PT3973959T (https=)
RS (1) RS62790B1 (https=)
SG (1) SG11202002253SA (https=)
SI (2) SI3687523T1 (https=)
SM (1) SMT202200171T1 (https=)
UA (1) UA125600C2 (https=)
WO (1) WO2019067373A1 (https=)
ZA (1) ZA202001646B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
RS57970B1 (sr) 2014-03-20 2019-01-31 Cymabay Therapeutics Inc Tretman intrahepatičkih holestatskih oboljenja
US12053445B2 (en) 2016-03-31 2024-08-06 Genfit Methods of treatment of cholestatic diseases
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
MX2022009776A (es) * 2020-02-10 2022-09-09 Genfit Tratamiento de la colangitis biliar primaria con elafibranor.
CN115884765A (zh) 2020-08-26 2023-03-31 基恩菲特公司 用于治疗原发性胆汁性胆管炎的组合物和方法
CN116490191A (zh) * 2020-10-20 2023-07-25 葛兰素史克知识产权第二有限公司 治疗胆汁淤积性瘙痒的方法
US20220241228A1 (en) 2021-02-01 2022-08-04 Cymabay Therapeutics, Inc. Treatment of cholangiopathies
JP2026509094A (ja) 2023-01-29 2026-03-17 シマベイ セラピューティクス, インコーポレーテッド 尿毒症性掻痒の治療
WO2024159051A1 (en) 2023-01-29 2024-08-02 Cymabay Therapeutics, Inc. Treatment of chronic pruritic dermatoses
WO2025250635A1 (en) * 2024-05-28 2025-12-04 Avior, Inc. Use of nalmefene hydrochloride buccal films in treating liver disease associated pruritus
US20260060948A1 (en) 2024-07-31 2026-03-05 Cymabay Therapeutics, Inc. Methods for treating liver disease
CN121023009A (zh) * 2025-10-31 2025-11-28 浙江大学医学院附属妇产科医院(浙江省妇女医院、浙江省妇女保健院) 基于唾液样本的妊娠期肝内胆汁淤积症易感基因多重pcr—ngs筛查方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042478A2 (en) 2003-09-19 2005-05-12 Janssen Pharmaceutica, N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
RS57970B1 (sr) 2014-03-20 2019-01-31 Cymabay Therapeutics Inc Tretman intrahepatičkih holestatskih oboljenja
JP2020533339A (ja) * 2017-09-13 2020-11-19 ノバルティス アーゲー Fxrアゴニストを含む組合せ

Also Published As

Publication number Publication date
EP3687523A1 (en) 2020-08-05
SI3687523T1 (sl) 2022-05-31
MX392537B (es) 2025-03-04
SMT202200171T1 (it) 2022-05-12
AU2021254641B2 (en) 2022-02-24
AU2018342323A1 (en) 2020-04-16
RS62790B1 (sr) 2022-02-28
CN111132675A (zh) 2020-05-08
IL273569B (en) 2021-12-01
ES2902349T3 (es) 2022-03-28
EP3687523B1 (en) 2021-11-03
WO2019067373A1 (en) 2019-04-04
MX2020007273A (es) 2022-05-23
SG11202002253SA (en) 2020-04-29
IL288340B1 (en) 2023-01-01
EP3973959B1 (en) 2024-12-11
ES3012120T3 (en) 2025-04-08
PT3687523T (pt) 2021-12-06
KR20200058458A (ko) 2020-05-27
HUE070033T2 (hu) 2025-05-28
AU2021254641A1 (en) 2021-11-18
EP3973959B8 (en) 2025-01-15
PL3687523T3 (pl) 2022-02-21
UA125600C2 (uk) 2022-04-27
PL3973959T3 (pl) 2025-03-24
JP7023371B2 (ja) 2022-02-21
US20190105291A1 (en) 2019-04-11
BR112020005074A2 (pt) 2020-09-15
CN111132675B (zh) 2023-04-25
RU2020114644A (ru) 2021-10-27
LT3687523T (lt) 2022-03-25
NZ762976A (en) 2021-11-26
LT3973959T (lt) 2025-01-10
PT3973959T (pt) 2025-01-24
SI3973959T1 (sl) 2025-03-31
IL288340B2 (en) 2023-05-01
EP4523744A3 (en) 2025-06-04
US20210283078A1 (en) 2021-09-16
IL288340A (en) 2022-01-01
IL273569A (en) 2020-05-31
DK3973959T3 (da) 2025-01-20
ZA202001646B (en) 2021-08-25
EP4523744A2 (en) 2025-03-19
HRP20250022T1 (hr) 2025-03-14
CA3076614A1 (en) 2019-04-04
CA3076614C (en) 2023-02-07
HRP20212010T1 (hr) 2022-04-01
AU2018342323B2 (en) 2021-09-23
KR102376794B1 (ko) 2022-03-18
RU2020114644A3 (https=) 2022-02-14
EP3973959A1 (en) 2022-03-30
JP2020535225A (ja) 2020-12-03
HUE057377T2 (hu) 2022-05-28
FI3973959T3 (fi) 2025-02-03

Similar Documents

Publication Publication Date Title
CY1124894T1 (el) Θεραπευτικη αντιμετωπιση χολοστατικου κνησμου με σελαδελπαρη
CY1122602T1 (el) Αντιμετωπιση των nafld και nash
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
IL268709A (en) Radiation source
ECSP17015977A (es) Terapia de combinacion
CY1120927T1 (el) Αγωγη των ενδοηπατικων χολοστατικων νοσων
ECSP17029371A (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CY1125465T1 (el) Σελαδελπαρη για αγωγη της πρωτοπαθους χολικης χολαγγειιτιδας
IL264203A (en) Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy
DK3612624T3 (da) Genterapi
DK3622953T3 (da) Kombinationsbehandling af cancer
PT3319995T (pt) Terapêutica combinada de um conjugado anticorpo anti-her2-fármaco com um inibidor de bcl-2
EP3479227A4 (en) CORRELATION OF MULTIPLE SOURCES
EP3636271C0 (en) THERAPEUTIC AGENT AGAINST DILATED CARDIOMYOPATHY
EP3843748C0 (en) COMBINATION THERAPY
JOP20200034B1 (ar) تركيبة للتنشيط المتحكم فيه للمبيض
EP3600371A4 (en) AGAINST ERG THERAPY
IT201700100732A1 (it) Sorgente ionica
EP3717020A4 (en) RAS TARGETED THERAPEUTIC
DK3552506T3 (da) Underlivsbeklædning
EP3801506A4 (en) POLYTHERAPY
EP3515442A4 (en) ADJUSTMENT
GEAP201814364A (en) Radial-squeezing machine
GEAP201814238A (en) Wall heat-insulating block
UA98239U (xx) Солегіпсовий спелеоматеріал